SomaLogic expands agreement with Novo Nordisk to 2025
05 Setembro 2023 - 9:30AM
SomaLogic, Inc., a leader in proteomics technology, announced today
that it is extending its collaborative agreement with global
healthcare innovator, Novo Nordisk. As part of the agreement, which
now extends into the end of 2025, Novo Nordisk will expand its use
of the SomaScan® proteomics platform in drug research and
development. Novo Nordisk will also use SomaLogic’s SomaSignal®
tests for investigations into cardiometabolic and other diseases.
This extension builds upon a previous agreement between the two
companies, which was announced in 2021.
“SomaLogic has been very pleased with our partnership with Novo
Nordisk which spans more than a decade,” said SomaLogic Chief
Executive Officer Adam Taich. “We are proud that our SomaScan
platform is being used in their research and development of new
potential treatments for serious chronic diseases.”
Novo Nordisk previously partnered with SomaLogic to provide
proteins of interest that expanded the SomaScan platform’s previous
offering to its current industry-leading offering of more than
7,000 proteins. SomaLogic’s proprietary protein detection and
analysis technology measures how proteins function and interact,
supporting researchers in drug research and development, and
biomarker identification efforts.
For more than twenty years, SomaLogic has grown from its roots
in the research lab to become a global leader in proteomics
technology. With this lineage comes a deep understanding of the
needs that life science researchers have as they progress complex
studies that demand both precision as well as skill and efficiency.
The extension of this partnership with Novo Nordisk is the latest
example of SomaLogic’s dedication to delivering the quality and
quantity of biological insights to meet these needs - from bench to
bedside.
About SomaLogic SomaLogic is
catalyzing drug research and development and biomarker
identification as a global leader in proteomics technology. With a
single 55 microliter plasma or serum sample, SomaLogic can run
7,000 protein measurements, covering more than a third of the
approximately 20,000 proteins in the human body. For more than 20
years we’ve supported pharmaceutical companies, and academic and
contract research organizations who rely on our protein detection
and analysis technologies to fuel drug, disease, and treatment
discoveries in such areas as oncology, diabetes, and
cardiovascular, liver and metabolic diseases. Find out more at
www.somalogic.com and follow @somalogic on LinkedIn.
Forward Looking Statements Disclaimer This
press release contains certain forward-looking statements within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995 and other federal
securities laws. All statements, other than statements of
historical fact included in this press release, regarding our
strategy, future operations, financial position, estimated
revenues, projections, prospects, plans and objectives of
management are forward-looking statements. These forward-looking
statements generally are identified by the words “believe,”
“project,” “forecast,” “guidance,” “expect,” “anticipate,”
“estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,”
“may,” “should,” “will,” “would,” “will be,” “continue,” “will
likely result,” “possible,” “potential,” “predict,” “pursue,”
“target” and similar expressions, although not all forward-looking
statements contain such identifying words. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Forward-looking statements do not guarantee future
performance and involve known and unknown risks, uncertainties and
other factors. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including factors which are beyond SomaLogic’s control.
You should carefully consider these risks and uncertainties,
including, but not limited to, those factors described under Part
I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and
other filings we make with the Securities and Exchange Commission.
These filings identify and address important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and SomaLogic assumes no obligation and does not intend
to update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Should one
or more of these risks or uncertainties materialize, or should any
of the assumptions prove incorrect, actual results may vary in
material respects from those projected in these forward-looking
statements. The Company will not and does not undertake any
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as may be required under applicable securities
laws.
Media Contact Emilia Costales
720-798-5054 ecostales@somalogic.com
Investor ContactMarissa
Bychinvestors@somalogic.com
SomaLogic (NASDAQ:SLGC)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
SomaLogic (NASDAQ:SLGC)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024